Beers DR, Appel SH (2019) Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies. Lancet Neurol 18:211–220

CAS  Article  Google Scholar 

Brown RH, Hauser SL, Harrington H, Weiner HL (1986) Failure of immunosuppression with a ten- to 14-day course of high-dose intravenous cyclophosphamide to alter the progression of amyotrophic lateral sclerosis. Arch Neurol 43:383–384

Article  Google Scholar 

Gourie-Devi M, Nalini A, Subbakrishna DK (1997) Temporary amelioration of symptoms with intravenous cyclophosphamide in amyotrophic lateral sclerosis. J Neurol Sci 150:167–172

CAS  Article  Google Scholar 

Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, Shaw PJ, Simmons Z, van den Berg LH (2017) Amyotrophic lateral sclerosis. Nature Reviews Disease Primers 3

Jaiswal MK (2018) Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. Med Res Rev 39:733–748

Article  Google Scholar 

Ransohoff RM (2016) How neuroinflammation contributes to neurodegeneration. Science 353:777–783

CAS  Article  Google Scholar 

Ringel SP, Murphy JR, Alderson MK, Bryan W, England JD, Miller RG, Petajan JH, Smith SA, Roelofs RI, Ziter F (1993) The natural history of amyotrophic lateral sclerosis. Neurology 43:1316–1322

CAS  Article  Google Scholar 

Roche JC, Rojas-Garcia R, Scott KM, Scotton W, Ellis CE, Burman R, Wijesekera L, Turner MR, Leigh PN, Shaw CE, Al-Chalabi A (2012) A proposed staging system for amyotrophic lateral sclerosis. Brain 135:847–852

Article  Google Scholar 

Smith SA, Miller RG, Murphy JR, Ringel SP (1994) Treatment of ALS with high dose pulse cyclophosphamide. J Neurol Sci 124(Suppl):84–87

Article  Google Scholar